News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer.
Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not looking so rosy for Janssen’s HIV vaccine candidate.
The top stories:
Precision drug could redefine depression treatment
A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).
Oncobiotic cancer drug could be a step forward for science
The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients.
Early trial data confirms drug’s tumour targeting potential
Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial.
New drug reduced renal damage in septic patients
A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint.
Experimental HIV vaccine safe but ineffective
An investigational HIV vaccine regimen was safe but did not provide protection against HIV, an independent data and safety monitoring board (DSMB) has determined.
